American Century Companies Inc. Boosts Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

American Century Companies Inc. increased its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 7.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 269,971 shares of the biopharmaceutical company’s stock after purchasing an additional 18,733 shares during the quarter. American Century Companies Inc.’s holdings in Vanda Pharmaceuticals were worth $1,525,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of VNDA. Aristides Capital LLC purchased a new position in shares of Vanda Pharmaceuticals in the 4th quarter valued at about $272,000. GSA Capital Partners LLP lifted its stake in Vanda Pharmaceuticals by 39.8% during the fourth quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company’s stock worth $2,396,000 after purchasing an additional 161,737 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in Vanda Pharmaceuticals by 17.6% during the first quarter. Los Angeles Capital Management LLC now owns 431,224 shares of the biopharmaceutical company’s stock worth $1,772,000 after purchasing an additional 64,670 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Vanda Pharmaceuticals by 65.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 4,387 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in Vanda Pharmaceuticals by 70.1% during the first quarter. BNP Paribas Financial Markets now owns 101,363 shares of the biopharmaceutical company’s stock worth $417,000 after purchasing an additional 41,767 shares during the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Trading Down 1.5 %

NASDAQ:VNDA opened at $4.67 on Monday. The firm has a market cap of $272.21 million, a P/E ratio of -58.38 and a beta of 0.77. The stock’s 50 day simple moving average is $5.28 and its 200-day simple moving average is $5.15. Vanda Pharmaceuticals Inc. has a 12-month low of $3.30 and a 12-month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. The business had revenue of $50.47 million for the quarter. Research analysts forecast that Vanda Pharmaceuticals Inc. will post -0.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on VNDA shares. StockNews.com started coverage on Vanda Pharmaceuticals in a research note on Monday. They set a “hold” rating for the company. Cantor Fitzgerald boosted their target price on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.